Scarica l'app Stockscreener
95.77
1.06%
-1.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALC Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$96.80
Aprire:
$95.96
Volume 24 ore:
2.44M
Relative Volume:
1.84
Capitalizzazione di mercato:
$47.37B
Reddito:
$9.91B
Utile/perdita netta:
$1.02B
Rapporto P/E:
46.72
EPS:
2.05
Flusso di cassa netto:
$665.00M
1 W Prestazione:
+5.75%
1M Prestazione:
+4.13%
6M Prestazione:
-3.88%
1 anno Prestazione:
+14.98%
Intervallo 1D:
$95.59
$96.38
Intervallo di 1 settimana:
$90.64
$97.40
Portata 52W:
$77.54
$101.10
Alcon Inc Stock (ALC) Company Profile
Nome
Alcon Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ALC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
95.77 | 47.37B | 9.91B | 1.02B | 665.00M | 2.05 |
|
ISRG
Intuitive Surgical Inc
|
491.84 | 181.97B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
227.50 | 66.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
RMD
Resmed Inc
|
219.94 | 32.31B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
33.75 | 17.31B | 17.28B | 108.00M | 391.00M | 0.20 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-01-24 | Reiterato | Needham | Buy |
| 2025-01-10 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Reiterato | Needham | Buy |
| 2024-11-12 | Reiterato | Needham | Buy |
| 2024-10-10 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Iniziato | Goldman | Buy |
| 2024-03-14 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Iniziato | Bernstein | Outperform |
| 2023-12-18 | Downgrade | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Iniziato | Stifel | Buy |
| 2023-12-04 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Aggiornamento | Societe Generale | Sell → Hold |
| 2022-12-22 | Iniziato | Mizuho | Buy |
| 2022-11-17 | Downgrade | Societe Generale | Hold → Sell |
| 2022-08-11 | Downgrade | Societe Generale | Buy → Hold |
| 2022-05-13 | Ripresa | Credit Suisse | Outperform |
| 2022-05-12 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Iniziato | Needham | Buy |
| 2022-03-11 | Iniziato | BofA Securities | Buy |
| 2022-01-18 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Iniziato | Oppenheimer | Perform |
| 2021-07-14 | Iniziato | Deutsche Bank | Buy |
| 2021-05-06 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-03-22 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-11-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-07-06 | Downgrade | Citigroup | Neutral → Sell |
| 2020-07-06 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Aggiornamento | Argus | Hold → Buy |
| 2020-03-24 | Aggiornamento | Societe Generale | Sell → Hold |
| 2020-03-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-26 | Aggiornamento | Berenberg | Hold → Buy |
| 2020-01-08 | Iniziato | Argus | Hold |
| 2019-10-29 | Iniziato | Stephens | Equal-Weight |
| 2019-08-21 | Reiterato | BofA/Merrill | Neutral |
| 2019-06-24 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-06-14 | Iniziato | BTIG Research | Neutral |
| 2019-05-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-05-02 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Alcon Inc Borsa (ALC) Ultime notizie
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval - MSN
Stifel maintains Alcon stock Buy rating, $100 target By Investing.com - Investing.com Australia
Citi maintains Alcon stock Buy rating, CHF99.00 target By Investing.com - Investing.com South Africa
Mizuho lifts Alcon stock price target to $120, maintains Outperform By Investing.com - Investing.com Canada
Taxation With Representation: Norton Rose, Latham, Ashurst - Law360
Alcon stock price target raised to $110 at Needham - Investing.com India
Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Mizuho lifts Alcon stock price target to $120, maintains Outperform - Investing.com
Jefferies raises Alcon stock price target to $115, maintains Buy - Investing.com India
Jefferies raises Alcon stock price target to $115, maintains Buy By Investing.com - Investing.com South Africa
Citi maintains Alcon stock Buy rating, CHF99.00 target - Investing.com India
Alcon (VTX:ALC) ascends 4.7% this week, taking five-year gains to 80% - Yahoo Finance
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Cell Therapy for Corneal Endothelial Disease - Vision Monday
Alcon Inc’s Acquisition of LENSAR Inc - Global Legal Chronicle
Alcon's Future Looks Fruitful as New Innovation and Commercial Execution Spark Market Outperformance - Morningstar
All eyes on ophthalmic cell therapy space as Alcon takes majority stake in Aurion - FirstWord Pharma
Alcon buys majority stake in IPO-seeking cell therapy startup Aurion - BioPharma Dive
Alcon claims control of cell therapy firm Aurion - pharmaphorum
Alcon acquires majority interest in Aurion Biotech - Ophthalmology Times
Alcon secures majority stake in Aurion, deposes CEO - PharmaLive
Related Content: Alcon to Acquire LENSAR | Business | Mar 2025 - Photonics.com
Alcon to buy Lensar in deal worth up to $430M - The Business Journals
Alcon to Acquire LENSAR | Business | Mar 2025 - Photonics.com
Alcon upgraded at BofA Securities to Buy on earnings growth potential - MSN
Alcon acquires majority interest in Aurion Biotech to advance first-ever corneal cell therapy candidate - BSA bureau
Aurion CEO is out as Alcon takes majority stake in cell therapy startup - Endpoints News
Alcon acquires majority stake in Aurion Biotech By Investing.com - Investing.com South Africa
Alcon buys majority stake in Aurion Biotech (ALC:NYSE) - Seeking Alpha
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease - Sharewise
Alcon acquires majority stake in Aurion Biotech - Investing.com
Alcon Acquires Majority Interest In Aurion Biotech, Inc. To Advance Innovative Cell Therapy For Corneal Endothelial Disease - Marketscreener.com
Alcon signs merger agreement to acquire Lensar - MSN
Stifel maintains Alcon stock Buy rating, $100 price target By Investing.com - Investing.com Australia
Stifel maintains Alcon stock Buy rating with $100 target By Investing.com - Investing.com Australia
Bernstein maintains Alcon Outperform rating, $110.50 target - Investing.com
Alcon lines up Lensar deal to expand laser cataract surgery options - Optics.org
Alcon Gets EU Nod for Clareon Vivity Intraocular Lens - MPO-mag
Bank of America Upgrades Alcon (ALC) Stock Rating Amid Growth Pr - GuruFocus.com
HSBC and BofA have differing views on Alcon ahead of product launches - TradingView
ALC Stock Rises Following the Merger Agreement With LENSAR - TradingView
Stifel maintains Alcon stock Buy rating, $100 price target - Investing.com India
BofA raises Alcon stock rating, boosts target to CHF96 By Investing.com - Investing.com South Africa
Alcon agrees to purchase LENSAR - Ophthalmology Times
Stifel maintains Alcon stock Buy rating with $100 target - Investing.com India
Switzerland: Alcon agrees acquisition of Lensar for up to US$430m - Investors in Healthcare
Alcon Gets CE Mark for Clareon Vivity Intraocular Lens - Marketscreener.com
Alcon to Begin Commercial Rollout of Vivity Lens in Europe by Q2 - Marketscreener.com
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities - Business Wire
Alcon Agrees to Acquire Lensar, Inc. for Up to $430 Million - Vision Monday
Alcon Inc Azioni (ALC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.20%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):